Glipsov M 20/500 Tablet PR is a fixed-dose combination medication containing Metformin 500 mg and Teneligliptin 20 mg, indicated for the management of type 2 diabetes mellitus. Metformin, a biguanide, primarily acts by decreasing hepatic glucose production, improving insulin sensitivity, and enhancing peripheral glucose uptake, thereby aiding in glycemic control. Teneligliptin, a dipeptidyl peptidase-4 (DPP-4) inhibitor, increases endogenous incretin levels, which in turn stimulate insulin secretion and suppress glucagon release in a glucose-dependent manner. The combination of these agents provides complementary mechanisms to effectively reduce blood glucose levels. Glipsov M 20/500 Tablet PR is typically prescribed when monotherapy with either agent is insufficient to achieve adequate glycemic control. It is administered orally, usually once or twice daily with meals, to minimize gastrointestinal side effects commonly associated with Metformin. The prolonged-release formulation ensures sustained drug release, promoting better patient compliance and steady plasma concentrations. Caution is advised in patients with renal impairment, hepatic dysfunction, or cardiovascular disease. Regular monitoring of blood glucose levels, renal function, and potential adverse effects is recommended during therapy. This combination therapy should be used as part of a comprehensive diabetes management plan including diet and exercise.